Table q1_q4_2019_prescription_drugs_wac

Table: q1_q4_2019_prescription_drugs_wac_increases , manufacturer_name like B*

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z *

oshpd_id	manufacturer_name	date_reported	ndc_number	drug_product_description	wac_effective_date	wac_increase_amount	wac_after_increase	patent_expiration_date	drug_source_type	unit_sales_volume_in_us	unit_sales_volume_non_public_indicator	cost_increase_factors	cost_increase_factors_non_public_indicator	change_improvement_description	change_improvement_non_public_indicator	acquisition_date	company_acquired_from	acquisition_price	acquisition_price_non_public_indicator	acquisition_price_comment	wac_at_acquisition	wac_year_prior_to_acquisition	year_drug_introduced_to_market	wac_at_intro_to_market	supporting_documents	general_comments
Rx0000013	B. Braun Medical Inc.	09/30/2019	00264780020	0.9% NACL INJ USP 250ML	07/01/2019	5.12	54.96	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The case prices noted herein are B. Braun’s distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. * This NDC was not acquired by B. Braun within the last 5 years.
Rx0000013	B. Braun Medical Inc.	09/30/2019	00264180032	0.9% NACL INJ. PAB 100ML IN 150ML BAG	07/01/2019	24.91	120.96	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The case prices noted herein are B. Braun’s distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. * This NDC was not acquired by B. Braun within the last 5 years.
Rx0000013	B. Braun Medical Inc.	09/30/2019	00264180031	0.9% NACL INJ. PAB 50ML IN 100ML BAG	07/01/2019	34.94	158.76	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The case prices noted herein are B. Braun’s distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. * This NDC was not acquired by B. Braun within the last 5 years.
Rx0000013	B. Braun Medical Inc.	09/30/2019	00264738860	0.9% SODIUM CHLORIDE IRR, USP, 3L BAG	07/01/2019	4.36	52.36	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The case prices noted herein are B. Braun’s distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. * This NDC was not acquired by B. Braun within the last 5 years.
Rx0000013	B. Braun Medical Inc.	09/30/2019	00264314311	1G CEFTAZIDIME FOR INJ USP/DEX INJ USP	07/01/2019	90.81	357.60	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The case prices noted herein are B. Braun’s distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. * This NDC was not acquired by B. Braun within the last 5 years.
Rx0000013	B. Braun Medical Inc.	09/30/2019	00264314511	2G CEFTAZIDIME FOR INJ USP/DEX INJ USP	07/01/2019	32.92	416.88	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The case prices noted herein are B. Braun’s distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. * This NDC was not acquired by B. Braun within the last 5 years.
Rx0000013	B. Braun Medical Inc.	09/30/2019	00264751000	5% DEXTROSE INJ USP 1L	07/01/2019	10.40	36.84	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The case prices noted herein are B. Braun’s distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. * This NDC was not acquired by B. Braun within the last 5 years.
Rx0000013	B. Braun Medical Inc.	09/30/2019	00264151032	5%D INJ PAB 100ML IN 150ML BAG	07/01/2019	29.32	120.96	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The case prices noted herein are B. Braun’s distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. * This NDC was not acquired by B. Braun within the last 5 years.
Rx0000013	B. Braun Medical Inc.	09/30/2019	00264151031	5%D INJ PAB 50ML IN 100ML BAG	07/01/2019	38.47	158.76	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The case prices noted herein are B. Braun’s distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. * This NDC was not acquired by B. Braun within the last 5 years.
Rx0000013	B. Braun Medical Inc.	09/30/2019	00264310311	CEFAZOLIN 1 GM IN DUPLEX	07/01/2019	72.96	219.84	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The case prices noted herein are B. Braun’s distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. * This NDC was not acquired by B. Braun within the last 5 years.
Rx0000013	B. Braun Medical Inc.	09/30/2019	00264310511	CEFAZOLIN 2G IN DUPLEX	07/01/2019	54.24	274.56	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The case prices noted herein are B. Braun’s distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. * This NDC was not acquired by B. Braun within the last 5 years.
Rx0000013	B. Braun Medical Inc.	09/30/2019	00264319311	CEFEPIME 1G FOR INJECTION USP	07/01/2019	84.18	382.32	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The case prices noted herein are B. Braun’s distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. * This NDC was not acquired by B. Braun within the last 5 years.
Rx0000013	B. Braun Medical Inc.	09/30/2019	00264319511	CEFEPIME 2G FOR INJECTION USP	07/01/2019	133.25	582.96	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The case prices noted herein are B. Braun’s distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. * This NDC was not acquired by B. Braun within the last 5 years.
Rx0000013	B. Braun Medical Inc.	09/30/2019	00264317311	CEFOTETAN FOR INJ.(1G)DEXTROSE INJECTION	07/01/2019	50.84	435.36	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The case prices noted herein are B. Braun’s distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. * This NDC was not acquired by B. Braun within the last 5 years.
Rx0000013	B. Braun Medical Inc.	09/30/2019	00264317511	CEFOTETAN FOR INJ.(2G)DEXTROSE INJECTION	07/01/2019	72.63	622.56	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The case prices noted herein are B. Braun’s distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. * This NDC was not acquired by B. Braun within the last 5 years.
Rx0000013	B. Braun Medical Inc.	09/30/2019	00264315511	CEFTRIAXONE FOR INJ(2G) DEXTROSE FOR INJ	07/01/2019	133.51	584.16	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The case prices noted herein are B. Braun’s distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. * This NDC was not acquired by B. Braun within the last 5 years.
Rx0000013	B. Braun Medical Inc.	09/30/2019	00264315311	CEFTRIAXONE FOR INJ.(1G)DEXTROSE FOR INJ	07/01/2019	57.26	360.72	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The case prices noted herein are B. Braun’s distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. * This NDC was not acquired by B. Braun within the last 5 years.
Rx0000013	B. Braun Medical Inc.	03/31/2019	00264957710	Heparin in Dextrose Injection	01/01/2019	46.85	281.09	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The case prices noted herein are B. Braun Medical Inc.’s (“B. Braun”) distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers.
Rx0000013	B. Braun Medical Inc.	09/30/2019	00264958720	HEPARIN SODIUM 100 UNITS/ML IN 5% DEX	07/01/2019	92.64	337.44	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The case prices noted herein are B. Braun’s distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. * This NDC was not acquired by B. Braun within the last 5 years.
Rx0000013	B. Braun Medical Inc.	09/30/2019	00264957710	HEPARIN SODIUM 50 UNITS/ML IN 5% DEX	07/01/2019	39.55	320.64	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The case prices noted herein are B. Braun’s distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. * This NDC was not acquired by B. Braun within the last 5 years.
Rx0000013	B. Braun Medical Inc.	03/31/2019	00264958720	Heparin Sodium in 5% Dextrose Injection (100 U/ML)	01/01/2019	40.80	244.80	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The case prices noted herein are B. Braun’s distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers.
Rx0000013	B. Braun Medical Inc.	09/30/2019	00264738960	LACTATED RINGERS IRRIGATION, USP,3L BAG	07/01/2019	13.78	56.28	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The case prices noted herein are B. Braun’s distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. * This NDC was not acquired by B. Braun within the last 5 years.
Rx0000013	B. Braun Medical Inc.	09/30/2019	00264191507	PROCALAMINE INJ SSGL 1L	07/01/2019	43.51	205.44	06/20/2020	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The case prices noted herein are B. Braun’s distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. * This NDC was not acquired by B. Braun within the last 5 years.
Rx0000096	Bausch + Lomb, Inc.	03/31/2019	24208035305	ALREX® (loteprednol etabonate ophthalmic suspension 0.2%)	01/18/2019	12.77	225.60	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years.
Rx0000096	Bausch + Lomb, Inc.	03/31/2019	24208035310	ALREX® (loteprednol etabonate ophthalmic suspension 0.2%)	01/18/2019	25.54	451.19	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years.
Rx0000096	Bausch + Lomb, Inc.	03/31/2019	24208062901	BEPREVE™ Ophthalmic Solution USP, 1.5%	01/18/2019	23.50	415.18	09/05/2024	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years.
Rx0000096	Bausch + Lomb, Inc.	03/31/2019	24208062902	BEPREVE™ Ophthalmic Solution USP, 1.5%	01/18/2019	12.29	217.08	09/06/2024	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years.
Rx0000096	Bausch + Lomb, Inc.	03/31/2019	24208044605	BESIVANCE® (besifloxacin ophthalmic suspension 0.6%)	01/18/2019	9.59	169.36	11/07/2030	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years.
Rx0000096	Bausch + Lomb, Inc.	03/31/2019	24208000401	ISTALOL™ Ophthalmic Solution USP, 0.5%	01/18/2019	9.76	172.42	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years.
Rx0000096	Bausch + Lomb, Inc.	03/31/2019	24208000403	ISTALOL™ Ophthalmic Solution USP, 0.5%	01/18/2019	19.52	344.81	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years.
Rx0000096	Bausch + Lomb, Inc.	03/31/2019	24208080060	LACRISERT® (hydroxypropyl cellulose ophthalmic insert), 5mg	01/18/2019	28.38	501.36	None	Single Source Drug	None	1	None	1	None	1	02/05/2016	Aton Pharma, Inc.	None	1	None	398.10	None	2006	49.20	None	1.The product was introduced to the market before acquisition by Bausch + Lomb, Inc. The year of introduction and WAC at introduction contained in this report is the only information available to Bausch + Lomb. Bausch + Lomb has no knowledge of the actual date of introduction nor the WAC at introduction.
Rx0000096	Bausch + Lomb, Inc.	03/31/2019	24208050307	LOTEMAX® (loteprednol etabonate ophthalmic Gel 0.5%)	01/18/2019	10.80	190.73	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years.
Rx0000096	Bausch + Lomb, Inc.	03/31/2019	24208044335	LOTEMAX® (loteprednol etabonate ophthalmic Ointment 0.5%)	01/18/2019	15.19	268.38	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years.
Rx0000096	Bausch + Lomb, Inc.	03/31/2019	24208029905	LOTEMAX® (loteprednol etabonate ophthalmic suspension 0.5%)	01/18/2019	13.46	237.72	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years.
Rx0000096	Bausch + Lomb, Inc.	03/31/2019	24208029910	LOTEMAX® (loteprednol etabonate ophthalmic suspension 0.5%)	01/18/2019	26.91	475.39	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years.
Rx0000096	Bausch + Lomb, Inc.	03/31/2019	24208029915	LOTEMAX® (loteprednol etabonate ophthalmic suspension 0.5%)	01/18/2019	40.01	706.78	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years.
Rx0000096	Bausch + Lomb, Inc.	03/31/2019	24208053920	MIOCHOL®-E Intraocular Solution Reconstituted 20mg vial	01/18/2019	4.71	98.90	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years.
Rx0000096	Bausch + Lomb, Inc.	03/31/2019	24208060203	PROLENSA™ (bromfenac ophthalmic solution) 0.07% 3mL	01/18/2019	15.09	266.67	11/11/2033	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years.
Rx0000096	Bausch + Lomb, Inc.	03/31/2019	24208081205	TIMOPTIC® (Timolol Maleate Ophthalmic Solution) 0.25%, 5mL	01/18/2019	9.85	174.04	None	Innovator Multiple Source Drug	None	1	None	1	None	1	02/26/2018	Aton Pharma, Inc.	None	1	None	164.19	None	2009	14.94	None	1.The product was introduced to the market before acquisition by Bausch + Lomb, Inc. The year of introduction and WAC at introduction contained in this report is the only information available to Bausch + Lomb. Bausch + Lomb has no knowledge of the actual date of introduction nor the WAC at introduction.
Rx0000096	Bausch + Lomb, Inc.	03/31/2019	24208081310	TIMOPTIC® (Timolol Maleate Ophthalmic Solution) 0.50%, 10mL	01/18/2019	13.66	241.31	None	Innovator Multiple Source Drug	None	1	None	1	None	1	02/26/2018	Aton Pharma, Inc.	None	1	None	227.65	None	2009	34.30	None	1.The product was introduced to the market before acquisition by Bausch + Lomb, Inc. The year of introduction and WAC at introduction contained in this report is the only information available to Bausch + Lomb. Bausch + Lomb has no knowledge of the actual date of introduction nor the WAC at introduction.
Rx0000096	Bausch + Lomb, Inc.	03/31/2019	24208081305	TIMOPTIC® (Timolol Maleate Ophthalmic Solution) 0.50%, 5mL	01/18/2019	10.66	188.34	None	Innovator Multiple Source Drug	None	1	None	1	None	1	02/26/2018	Aton Pharma, Inc.	None	1	None	177.68	None	2009	17.68	None	1.The product was introduced to the market before acquisition by Bausch + Lomb, Inc. The year of introduction and WAC at introduction contained in this report is the only information available to Bausch + Lomb. Bausch + Lomb has no knowledge of the actual date of introduction nor the WAC at introduction.
Rx0000096	Bausch + Lomb, Inc.	03/31/2019	24208081425	TIMOPTIC-XE® (Timolol Maleate Ophthalmic Gel Forming Solution) 0.25%, 5mL	01/18/2019	11.53	203.62	None	Innovator Multiple Source Drug	None	1	None	1	None	1	11/06/2015	Aton Pharma, Inc.	None	1	None	332.12	None	2009	23.55	None	1.The product was introduced to the market before acquisition by Bausch + Lomb, Inc. The year of introduction and WAC at introduction contained in this report is the only information available to Bausch + Lomb. Bausch + Lomb has no knowledge of the actual date of introduction nor the WAC at introduction.
Rx0000096	Bausch + Lomb, Inc.	03/31/2019	24208081605	TIMOPTIC-XE® (Timolol Maleate Ophthalmic Gel Forming Solution) 0.50%, 5mL	01/18/2019	12.63	223.13	None	Innovator Multiple Source Drug	None	1	None	1	None	1	08/19/2015	Aton Pharma, Inc.	None	1	None	378.73	None	2009	28.00	None	1.The product was introduced to the market before acquisition by Bausch + Lomb, Inc. The year of introduction and WAC at introduction contained in this report is the only information available to Bausch + Lomb. Bausch + Lomb has no knowledge of the actual date of introduction nor the WAC at introduction.
Rx0000096	Bausch + Lomb, Inc.	03/31/2019	24208000202	VITRASE® Solution 2x200 Units/ML	01/18/2019	9.38	196.93	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years.
Rx0000096	Bausch + Lomb, Inc.	03/31/2019	24208053535	ZIRGAN™ (Ganciclovir Ophthalmic Gel 0.15%)	01/18/2019	19.88	351.26	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years.
Rx0000096	Bausch + Lomb, Inc.	03/31/2019	24208035805	ZYLET® (loteprednol etabonate 0.5% and tobramycin 0.3% ophthalmic Suspension)	01/18/2019	14.00	247.39	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years.
Rx0000096	Bausch + Lomb, Inc.	03/31/2019	24208035810	ZYLET® (loteprednol etabonate 0.5% and tobramycin 0.3% ophthalmic Suspension)	01/18/2019	28.01	494.80	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years.
Rx0000024	Bayer	03/31/2019	50419048201	Angeliq Oral Tablet 0.25-0.5 MG	01/07/2019	8.87	186.18	10/22/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000024	Bayer	03/31/2019	50419048203	Angeliq Oral Tablet 0.25-0.5 MG	01/07/2019	26.60	558.52	10/22/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000024	Bayer	03/31/2019	50419048301	Angeliq Oral Tablet 0.5-1 MG	01/07/2019	8.87	186.18	10/22/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000024	Bayer	03/31/2019	50419048303	Angeliq Oral Tablet 0.5-1 MG	01/07/2019	26.60	558.52	10/22/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000024	Bayer	03/31/2019	50419052401	Betaseron Subcutaneous Kit 0.3 MG	01/15/2019	35.03	542.64	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000024	Bayer	03/31/2019	50419052435	Betaseron Subcutaneous Kit 0.3 MG	01/15/2019	490.35	7596.85	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000024	Bayer	03/31/2019	50419040701	Beyaz Oral Tablet 3-0.02-0.451 MG	01/07/2019	9.99	209.82	02/08/2030	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000024	Bayer	03/31/2019	50419040703	Beyaz Oral Tablet 3-0.02-0.451 MG	01/07/2019	29.97	629.46	02/08/2030	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000024	Bayer	03/31/2019	50419077701	Cipro Oral Suspension Reconstituted 250 MG/5ML (5%)	01/07/2019	6.21	130.40	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000024	Bayer	03/31/2019	50419077301	Cipro Oral Suspension Reconstituted 500 MG/5ML (10%)	01/07/2019	7.25	152.32	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000024	Bayer	03/31/2019	50419049104	Climara Pro Transdermal Patch Weekly 0.045-0.015 MG/DAY	01/07/2019	10.06	211.29	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000024	Bayer	03/31/2019	50419045404	Climara Transdermal Patch Weekly 0.025 MG/24HR	01/07/2019	6.28	131.81	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000024	Bayer	03/31/2019	50419045604	Climara Transdermal Patch Weekly 0.0375 MG/24HR	01/07/2019	6.28	131.81	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000024	Bayer	03/31/2019	50419045101	Climara Transdermal Patch Weekly 0.05 MG/24HR	01/07/2019	1.57	32.95	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000024	Bayer	03/31/2019	50419045104	Climara Transdermal Patch Weekly 0.05 MG/24HR	01/07/2019	6.28	131.81	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000024	Bayer	03/31/2019	50419045904	Climara Transdermal Patch Weekly 0.06 MG/24HR	01/07/2019	6.28	131.81	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000024	Bayer	03/31/2019	50419045304	Climara Transdermal Patch Weekly 0.075 MG/24HR	01/07/2019	6.28	131.81	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000024	Bayer	03/31/2019	50419045201	Climara Transdermal Patch Weekly 0.1 MG/24HR	01/07/2019	1.57	32.95	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000024	Bayer	03/31/2019	50419045204	Climara Transdermal Patch Weekly 0.1 MG/24HR	01/07/2019	6.28	131.81	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000024	Bayer	03/31/2019	50419040901	Natazia Oral Tablet 3/2-2/2-3/1 MG	01/07/2019	9.99	209.82	01/30/2028	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000024	Bayer	03/31/2019	50419040903	Natazia Oral Tablet 3/2-2/2-3/1 MG	01/07/2019	29.97	629.46	01/30/2028	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000024	Bayer	06/30/2019	50419048858	NexAVAR Oral Tablet 200 MG	06/01/2019	560.83	19231.20	09/10/2028	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000024	Bayer	06/30/2019	50419017101	Stivarga Oral Tablet 40 MG	06/01/2019	168.45	5788.44	07/09/2032	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000024	Bayer	06/30/2019	50419017103	Stivarga Oral Tablet 40 MG	06/01/2019	505.34	17365.32	07/09/2032	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000024	Bayer	03/31/2019	50419040201	Yasmin 28 Oral Tablet 3-0.03 MG	01/07/2019	5.67	119.09	08/31/2020	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000024	Bayer	03/31/2019	50419040203	Yasmin 28 Oral Tablet 3-0.03 MG	01/07/2019	17.01	357.27	08/31/2020	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000024	Bayer	03/31/2019	50419040501	YAZ Oral Tablet 3-0.02 MG	01/07/2019	6.85	143.84	08/31/2020	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000024	Bayer	03/31/2019	50419040503	YAZ Oral Tablet 3-0.02 MG	01/07/2019	20.55	431.52	08/31/2020	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000373	Bio Products Laboratory Limited	12/31/2019	64208823407	Gammaplex 5% Intravenous Solution 10 GM/200ML	11/11/2019	85.90	1727.10	None	Single Source Drug	0	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Consistent with CA law and regulations, this report is limited to information that is otherwise in the public domain or publicly available. The product at issue was developed by the company and not acquired from a third party; therefore, the product acquisition fields in the report are not applicable and have been left blank. The company submits this report in good faith, without waiver of its objections to, or its right to interpret Cal. Health & Safety Code §§ 127677-79 and the implementing regulations.”
Rx0000373	Bio Products Laboratory Limited	12/31/2019	64208823408	Gammaplex 5% Intravenous Solution 20 GM/400ML	11/11/2019	171.80	3454.20	None	Single Source Drug	0	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Consistent with CA law and regulations, this report is limited to information that is otherwise in the public domain or publicly available. The product at issue was developed by the company and not acquired from a third party; therefore, the product acquisition fields in the report are not applicable and have been left blank. The company submits this report in good faith, without waiver of its objections to, or its right to interpret Cal. Health & Safety Code §§ 127677-79 and the implementing regulations.”
Rx0000373	Bio Products Laboratory Limited	12/31/2019	64208823406	Gammaplex 5% Intravenous Solution 5 GM/100ML	11/11/2019	42.95	863.55	None	Single Source Drug	0	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Consistent with CA law and regulations, this report is limited to information that is otherwise in the public domain or publicly available. The product at issue was developed by the company and not acquired from a third party; therefore, the product acquisition fields in the report are not applicable and have been left blank. The company submits this report in good faith, without waiver of its objections to, or its right to interpret Cal. Health & Safety Code §§ 127677-79 and the implementing regulations.”
Rx0000373	Bio Products Laboratory Limited	12/31/2019	64208823403	Gammaplex Intravenous Solution 10 GM/200ML	11/11/2019	85.90	1727.10	None	Single Source Drug	0	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Consistent with CA law and regulations, this report is limited to information that is otherwise in the public domain or publicly available. The product at issue was developed by the company and not acquired from a third party; therefore, the product acquisition fields in the report are not applicable and have been left blank. The company submits this report in good faith, without waiver of its objections to, or its right to interpret Cal. Health & Safety Code §§ 127677-79 and the implementing regulations.”
Rx0000373	Bio Products Laboratory Limited	12/31/2019	64208823404	Gammaplex Intravenous Solution 20 GM/400ML	11/11/2019	171.80	3454.20	None	Single Source Drug	0	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Consistent with CA law and regulations, this report is limited to information that is otherwise in the public domain or publicly available. The product at issue was developed by the company and not acquired from a third party; therefore, the product acquisition fields in the report are not applicable and have been left blank. The company submits this report in good faith, without waiver of its objections to, or its right to interpret Cal. Health & Safety Code §§ 127677-79 and the implementing regulations.”
Rx0000373	Bio Products Laboratory Limited	12/31/2019	64208823402	Gammaplex Intravenous Solution 5 GM/100ML	11/11/2019	42.95	863.55	None	Single Source Drug	0	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Consistent with CA law and regulations, this report is limited to information that is otherwise in the public domain or publicly available. The product at issue was developed by the company and not acquired from a third party; therefore, the product acquisition fields in the report are not applicable and have been left blank. The company submits this report in good faith, without waiver of its objections to, or its right to interpret Cal. Health & Safety Code §§ 127677-79 and the implementing regulations.”
Rx0000099	Biogen	03/31/2019	59627011103	Avonex® (interferon beta-1a) Lyophilized Formulation Administration Pack (4 x 30 mcg vial, IM injection)	01/01/2019	135.80	6925.75	09/15/2026	Single Source Drug	None	1	Multiple factors are considered when determining price increases, including the continued level of R&D investment in the product, as well as the product’s value to patients, present and future benefits to society, and fulfilling Biogen’s commitment to innovation, affordability and sustainability. Note that due to channel mix and increasing discounts and allowances, the net price increase this year in Biogen’s MS portfolio in totality is under 2% year over year.	None	This increase was not necessitated by a change or improvement in the product.	None	None	None	None	None	None	None	None	None	None	None	Avonex was not acquired by Biogen from another company in the last 5 years.
Rx0000099	Biogen	03/31/2019	59627033304	Avonex® (interferon beta-1a) PEN™ Prefilled Autoinjector Administration Pack (4 x 30 mcg syringe, IM injection)	01/01/2019	135.80	6925.75	09/15/2026	Single Source Drug	None	1	Multiple factors are considered when determining price increases, including the continued level of R&D investment in the product, as well as the product’s value to patients, present and future benefits to society, and fulfilling Biogen’s commitment to innovation, affordability and sustainability. Note that due to channel mix and increasing discounts and allowances, the net price increase this year in Biogen’s MS portfolio in totality is under 2% year over year.	None	This increase was not necessitated by a change or improvement in the product.	None	None	None	None	None	None	None	None	None	None	None	Avonex was not acquired by Biogen from another company in the last 5 years.
Rx0000099	Biogen	03/31/2019	59627022205	Avonex® (interferon beta-1a) Prefilled Syringe Administration Pack (4 x 30 mcg syringe, IM injection)	01/01/2019	135.80	6925.75	09/15/2026	Single Source Drug	None	1	Multiple factors are considered when determining price increases, including the continued level of R&D investment in the product, as well as the product’s value to patients, present and future benefits to society, and fulfilling Biogen’s commitment to innovation, affordability and sustainability. Note that due to channel mix and increasing discounts and allowances, the net price increase this year in Biogen’s MS portfolio in totality is under 2% year over year.	None	This increase was not necessitated by a change or improvement in the product.	None	None	None	None	None	None	None	None	None	None	None	Avonex was not acquired by Biogen from another company in the last 5 years.
Rx0000099	Biogen	03/31/2019	64406001101	Plegridy® (peginterferon beta-1a) PEN, Maintenance Pack	01/01/2019	135.80	6925.75	06/16/2027	Single Source Drug	None	1	Multiple factors are considered when determining price increases, including the continued level of R&D investment in the product, as well as the product’s value to patients, present and future benefits to society, and fulfilling Biogen’s commitment to innovation, affordability and sustainability. Note that due to channel mix and increasing discounts and allowances, the net price increase this year in Biogen’s MS portfolio in totality is under 2% year over year.	None	This increase was not necessitated by a change or improvement in the product.	None	None	None	None	None	None	None	None	None	None	None	Plegridy was not acquired by Biogen from another company in the last 5 years.
Rx0000099	Biogen	03/31/2019	64406001201	Plegridy® (peginterferon beta-1a) PEN, Starter Pack	01/01/2019	135.80	6925.75	06/16/2027	Single Source Drug	None	1	Multiple factors are considered when determining price increases, including the continued level of R&D investment in the product, as well as the product’s value to patients, present and future benefits to society, and fulfilling Biogen’s commitment to innovation, affordability and sustainability. Note that due to channel mix and increasing discounts and allowances, the net price increase this year in Biogen’s MS portfolio in totality is under 2% year over year.	None	This increase was not necessitated by a change or improvement in the product.	None	None	None	None	None	None	None	None	None	None	None	Plegridy was not acquired by Biogen from another company in the last 5 years.
Rx0000099	Biogen	03/31/2019	64406001501	Plegridy® (peginterferon beta-1a) Prefilled Syringe, Maintenance Pack	01/01/2019	135.80	6925.75	06/16/2027	Single Source Drug	None	1	Multiple factors are considered when determining price increases, including the continued level of R&D investment in the product, as well as the product’s value to patients, present and future benefits to society, and fulfilling Biogen’s commitment to innovation, affordability and sustainability. Note that due to channel mix and increasing discounts and allowances, the net price increase this year in Biogen’s MS portfolio in totality is under 2% year over year.	None	This increase was not necessitated by a change or improvement in the product.	None	None	None	None	None	None	None	None	None	None	None	Plegridy was not acquired by Biogen from another company in the last 5 years.
Rx0000099	Biogen	03/31/2019	64406001601	Plegridy® (peginterferon beta-1a) Prefilled Syringe, Starter Pack	01/01/2019	135.80	6925.75	06/16/2027	Single Source Drug	None	1	Multiple factors are considered when determining price increases, including the continued level of R&D investment in the product, as well as the product’s value to patients, present and future benefits to society, and fulfilling Biogen’s commitment to innovation, affordability and sustainability. Note that due to channel mix and increasing discounts and allowances, the net price increase this year in Biogen’s MS portfolio in totality is under 2% year over year.	None	This increase was not necessitated by a change or improvement in the product.	None	None	None	None	None	None	None	None	None	None	None	Plegridy was not acquired by Biogen from another company in the last 5 years.
Rx0000099	Biogen	03/31/2019	64406000501	Tecfidera® (dimethyl fumarate) Half Dose (120 mg) Capsules: 7-day bottle of 14 capsules	01/01/2019	103.10	1821.80	02/27/2028	Single Source Drug	None	1	Multiple factors are considered when determining price increases, including the continued level of R&D investment in the product, as well as the product’s value to patients, present and future benefits to society, and fulfilling Biogen’s commitment to innovation, affordability and sustainability. Note that due to channel mix and increasing discounts and allowances, the net price increase this year in Biogen’s MS portfolio in totality is under 2% year over year.	None	This increase was not necessitated by a change or improvement in the product.	None	None	None	None	None	None	None	None	None	None	None	Tecfidera was not acquired by Biogen from another company in the last 5 years.
Rx0000099	Biogen	03/31/2019	64406000602	Tecfidera® (dimethyl fumarate) Regular Dose (240 mg) Capsules: 30-day bottle of 60 capsules	01/01/2019	441.90	7807.45	02/27/2028	Single Source Drug	None	1	Multiple factors are considered when determining price increases, including the continued level of R&D investment in the product, as well as the product’s value to patients, present and future benefits to society, and fulfilling Biogen’s commitment to innovation, affordability and sustainability. Note that due to channel mix and increasing discounts and allowances, the net price increase this year in Biogen’s MS portfolio in totality is under 2% year over year.	None	This increase was not necessitated by a change or improvement in the product.	None	None	None	None	None	None	None	None	None	None	None	Tecfidera was not acquired by Biogen from another company in the last 5 years.
Rx0000099	Biogen	03/31/2019	64406000703	Tecfidera® (dimethyl fumarate) Starter Pack (30 day): 7-day bottle 120 mg capsules, quantity 14 and 23-day bottle 240 mg capsules, quantity 46	01/01/2019	441.90	7807.45	02/27/2028	Single Source Drug	None	1	Multiple factors are considered when determining price increases, including the continued level of R&D investment in the product, as well as the product’s value to patients, present and future benefits to society, and fulfilling Biogen’s commitment to innovation, affordability and sustainability. Note that due to channel mix and increasing discounts and allowances, the net price increase this year in Biogen’s MS portfolio in totality is under 2% year over year.	None	This increase was not necessitated by a change or improvement in the product.	None	None	None	None	None	None	None	None	None	None	None	Tecfidera was not acquired by Biogen from another company in the last 5 years.
Rx0000038	Boehringer Ingelheim	03/31/2019	00597000160	AGGRENOX 25 MG-200 MG CAPSULE	01/01/2019	41.77	563.88	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=149	For Column F there are no unexpired patents for this product per the Orange Book. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2019	00597000201	APTIVUS 100 MG/ML SOLUTION	01/01/2019	31.56	557.63	10/29/2019	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=151	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2019	00597000302	APTIVUS 250 MG CAPSULE	01/01/2019	94.70	1672.98	10/29/2019	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=150	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2019	00597008717	ATROVENT 17 MCG HFA INHALER	01/01/2019	28.75	388.10	01/17/2030	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=152	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2019	00597000601	CATAPRES 0.1 MG TABLET	01/01/2019	20.12	271.57	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=156	For Column F there are no unexpired patents for this product per the Orange Book. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2019	00597000701	CATAPRES 0.2 MG TABLET	01/01/2019	30.78	415.48	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=157	For Column F there are no unexpired patents for this product per the Orange Book. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2019	00597001101	CATAPRES 0.3 MG TABLET	01/01/2019	38.62	521.37	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=158	For Column F there are no unexpired patents for this product per the Orange Book. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2019	00597003134	CATAPRES-TTS 1 PATCH	01/01/2019	19.50	263.28	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=153	For Column F there are no unexpired patents for this product per the Orange Book. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2019	00597003234	CATAPRES-TTS 2 PATCH	01/01/2019	32.84	443.31	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=154	For Column F there are no unexpired patents for this product per the Orange Book. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2019	00597003334	CATAPRES-TTS 3 PATCH	01/01/2019	45.55	614.96	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=155	For Column F there are no unexpired patents for this product per the Orange Book. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2019	00597002402	COMBIVENT RESPIMAT 20-100 MCG	01/01/2019	29.80	402.31	10/16/2030	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=159	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2019	00597014130	GILOTRIF 20 MG TABLET	01/01/2019	652.38	8807.15	07/05/2030	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=160	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2019	00597013730	GILOTRIF 30 MG TABLET	01/01/2019	652.38	8807.15	07/05/2030	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=161	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2019	00597013830	GILOTRIF 40 MG TABLET	01/01/2019	652.38	8807.15	07/05/2030	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=162	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2019	00597015230	JARDIANCE 10 MG TABLET	01/01/2019	27.90	492.85	06/11/2034	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=163	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2019	00597015237	JARDIANCE 10 MG TABLET	01/01/2019	27.90	492.85	06/11/2034	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=164	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2019	00597015290	JARDIANCE 10 MG TABLET	01/01/2019	83.69	1478.54	06/11/2034	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=165	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2019	00597015330	JARDIANCE 25 MG TABLET	01/01/2019	27.90	492.85	06/11/2034	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=166	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2019	00597015337	JARDIANCE 25 MG TABLET	01/01/2019	27.90	492.85	06/11/2034	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=167	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2019	00597015390	JARDIANCE 25 MG TABLET	01/01/2019	83.69	1478.54	06/11/2034	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=168	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2019	00597014818	JENTADUETO 2.5 MG-1,000 MG TAB	01/01/2019	74.07	1308.51	06/04/2030	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=173	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2019	00597014860	JENTADUETO 2.5 MG-1,000 MG TAB	01/01/2019	24.69	436.17	06/04/2030	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=174	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2019	00597014618	JENTADUETO 2.5 MG-500 MG TAB	01/01/2019	74.07	1308.51	06/04/2030	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=169	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2019	00597014660	JENTADUETO 2.5 MG-500 MG TAB	01/01/2019	24.69	436.17	06/04/2030	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=170	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2019	00597014718	JENTADUETO 2.5 MG-850 MG TAB	01/01/2019	74.07	1308.51	06/04/2030	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=171	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2019	00597014760	JENTADUETO 2.5 MG-850 MG TAB	01/01/2019	24.69	436.17	06/04/2030	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=172	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2019	00597027073	JENTADUETO XR 2.5 MG-1,000 MG	01/01/2019	24.69	436.17	03/06/2033	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=175	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2019	00597027094	JENTADUETO XR 2.5 MG-1,000 MG	01/01/2019	74.07	1308.51	03/06/2033	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=176	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2019	00597027533	JENTADUETO XR 5 MG-1,000 MG TB	01/01/2019	24.69	436.17	03/06/2033	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=177	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2019	00597027581	JENTADUETO XR 5 MG-1,000 MG TB	01/01/2019	74.07	1308.51	03/06/2033	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=178	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2019	00597003937	MICARDIS 20 MG TABLET	01/01/2019	15.98	215.77	01/10/2020	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=179	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2019	00597004037	MICARDIS 40 MG TABLET	01/01/2019	15.98	215.77	01/10/2020	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=180	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2019	00597004137	MICARDIS 80 MG TABLET	01/01/2019	15.98	215.77	10/06/2022	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=181	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2019	00597004337	MICARDIS HCT 40-12.5 MG TABLET	01/01/2019	15.98	215.77	01/10/2020	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=183	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2019	00597004437	MICARDIS HCT 80-12.5 MG TABLET	01/01/2019	15.98	215.77	01/10/2020	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=184	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2019	00597004237	MICARDIS HCT 80-25 MG TABLET	01/01/2019	15.98	215.77	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=182	For Column F there are no unexpired patents for this product per the Orange Book. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2019	00597018390	MIRAPEX 0.125 MG TABLET	01/01/2019	46.81	631.88	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=186	For Column F there are no unexpired patents for this product per the Orange Book. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2019	00597018461	MIRAPEX 0.25 MG TABLET	01/01/2019	54.60	737.05	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=187	For Column F there are no unexpired patents for this product per the Orange Book. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2019	00597018490	MIRAPEX 0.25 MG TABLET	01/01/2019	46.81	631.88	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=188	For Column F there are no unexpired patents for this product per the Orange Book. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2019	00597018561	MIRAPEX 0.5 MG TABLET	01/01/2019	54.60	737.05	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=189	For Column F there are no unexpired patents for this product per the Orange Book. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2019	00597018590	MIRAPEX 0.5 MG TABLET	01/01/2019	46.81	631.88	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=190	For Column F there are no unexpired patents for this product per the Orange Book. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2019	00597010190	MIRAPEX 0.75 MG TABLET	01/01/2019	46.81	631.88	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=185	For Column F there are no unexpired patents for this product per the Orange Book. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2019	00597019061	MIRAPEX 1 MG TABLET	01/01/2019	54.60	737.05	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=191	For Column F there are no unexpired patents for this product per the Orange Book. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2019	00597019090	MIRAPEX 1 MG TABLET	01/01/2019	46.81	631.88	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=192	For Column F there are no unexpired patents for this product per the Orange Book. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2019	00597019161	MIRAPEX 1.5 MG TABLET	01/01/2019	54.60	737.05	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=193	For Column F there are no unexpired patents for this product per the Orange Book. After researching the highlighted compliance issues regarding the five year history and the two missing dates, it has been determined that the data we have supplied is correct. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2019	00597019190	MIRAPEX 1.5 MG TABLET	01/01/2019	46.81	631.88	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=194	For Column F there are no unexpired patents for this product per the Orange Book. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2019	00597010917	MIRAPEX ER 0.375 MG TABLET	01/01/2019	10.33	139.48	09/08/2029	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=195	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2019	00597010930	MIRAPEX ER 0.375 MG TABLET	01/01/2019	44.29	597.86	09/08/2029	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=196	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2019	00597028517	MIRAPEX ER 0.75 MG TABLET	01/01/2019	10.33	139.48	09/08/2029	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=201	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2019	00597028530	MIRAPEX ER 0.75 MG TABLET	01/01/2019	44.29	597.86	09/08/2029	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=202	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2019	00597011317	MIRAPEX ER 1.5 MG TABLET	01/01/2019	10.33	139.48	09/08/2029	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=197	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2019	00597011330	MIRAPEX ER 1.5 MG TABLET	01/01/2019	44.29	597.86	09/08/2029	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=198	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2019	00597028630	MIRAPEX ER 2.25 MG TABLET	01/01/2019	44.29	597.86	09/08/2029	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=203	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2019	00597011530	MIRAPEX ER 3 MG TABLET	01/01/2019	44.29	597.86	09/08/2029	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=199	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2019	00597028730	MIRAPEX ER 3.75 MG TABLET	01/01/2019	44.29	597.86	09/08/2029	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=204	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2019	00597011630	MIRAPEX ER 4.5 MG TABLET	01/01/2019	44.29	597.86	09/08/2029	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=200	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2019	00597003001	MOBIC 15 MG TABLET	01/01/2019	95.58	1290.37	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=206	For Column F there are no unexpired patents for this product per the Orange Book. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2019	00597002901	MOBIC 7.5 MG TABLET	01/01/2019	62.51	843.90	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=205	For Column F there are no unexpired patents for this product per the Orange Book. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2019	00597010854	PRADAXA 110 MG CAPSULE	01/01/2019	32.05	432.62	01/20/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=207	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2019	00597010860	PRADAXA 110 MG CAPSULE	01/01/2019	32.05	432.62	01/20/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=208	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2019	00597036055	PRADAXA 150 MG CAPSULE	01/01/2019	32.05	432.62	01/20/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=211	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2019	00597035509	PRADAXA 75 MG CAPSULE	01/01/2019	32.05	432.62	01/20/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=209	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2019	00597035556	PRADAXA 75 MG CAPSULE	01/01/2019	32.05	432.62	01/20/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=210	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2019	00597007541	SPIRIVA 18 MCG CP-HANDIHALER	01/01/2019	31.81	429.47	04/19/2030	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=213	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2019	00597007547	SPIRIVA 18 MCG CP-HANDIHALER	01/01/2019	95.44	1288.41	04/19/2030	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=214	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2019	00597016061	SPIRIVA RESPIMAT 1.25 MCG INH	01/01/2019	31.81	429.47	10/16/2030	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=217	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2019	00597010061	SPIRIVA RESPIMAT 2.5 MCG INH	01/01/2019	31.81	429.47	10/16/2030	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=216	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2019	00597015561	STIOLTO RESPIMAT INHAL SPRAY	01/01/2019	29.46	397.66	10/16/2030	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=218	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2019	00597019261	STRIVERDI RESPIMAT INHAL SPRAY	01/01/2019	15.69	211.83	10/16/2030	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=219	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2019	00597016818	SYNJARDY 12.5-1,000 MG TABLET	01/01/2019	83.69	1478.54	04/15/2027	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=222	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2019	00597016860	SYNJARDY 12.5-1,000 MG TABLET	01/01/2019	27.90	492.85	04/15/2027	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=223	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2019	00597018018	SYNJARDY 12.5-500 MG TABLET	01/01/2019	83.69	1478.54	04/15/2027	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=226	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2019	00597018060	SYNJARDY 12.5-500 MG TABLET	01/01/2019	27.90	492.85	04/15/2027	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=227	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2019	00597017518	SYNJARDY 5-1,000 MG TABLET	01/01/2019	83.69	1478.54	04/15/2027	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=224	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2019	00597017560	SYNJARDY 5-1,000 MG TABLET	01/01/2019	27.90	492.85	04/15/2027	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=225	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2019	00597015918	SYNJARDY 5-500 MG TABLET	01/01/2019	83.69	1478.54	04/15/2027	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=220	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2019	00597015960	SYNJARDY 5-500 MG TABLET	01/01/2019	27.90	492.85	04/15/2027	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=221	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2019	00597014030	TRADJENTA 5 MG TABLET	01/01/2019	24.69	436.17	03/05/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=228	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2019	00597014061	TRADJENTA 5 MG TABLET	01/01/2019	82.30	1453.90	03/05/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=229	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2019	00597014090	TRADJENTA 5 MG TABLET	01/01/2019	74.07	1308.51	03/05/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=230	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2019	00597012537	TWYNSTA 40-10 MG TABLET	01/01/2019	17.20	232.17	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=232	For Column F there are no unexpired patents for this product per the Orange Book. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2019	00597012437	TWYNSTA 40-5 MG TABLET	01/01/2019	17.20	232.17	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=231	For Column F there are no unexpired patents for this product per the Orange Book. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2019	00597012737	TWYNSTA 80-10 MG TABLET	01/01/2019	17.20	232.17	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=234	For Column F there are no unexpired patents for this product per the Orange Book. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2019	00597012637	TWYNSTA 80-5 MG TABLET	01/01/2019	17.20	232.17	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=233	For Column F there are no unexpired patents for this product per the Orange Book. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2019	00597004646	VIRAMUNE 200 MG TABLET	01/01/2019	11.97	211.43	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=235	For Column F there are no unexpired patents for this product per the Orange Book. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2019	00597004660	VIRAMUNE 200 MG TABLET	01/01/2019	51.28	906.02	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=236	For Column F there are no unexpired patents for this product per the Orange Book. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2019	00597004724	VIRAMUNE 50 MG/5 ML SUSP	01/01/2019	11.11	196.23	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=237	For Column F there are no unexpired patents for this product per the Orange Book. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2019	00597012990	VIRAMUNE XR 100 MG TABLET	01/01/2019	47.57	840.32	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=239	For Column F there are no unexpired patents for this product per the Orange Book. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2019	00597012330	VIRAMUNE XR 400 MG TABLET	01/01/2019	47.57	840.32	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=238	For Column F there are no unexpired patents for this product per the Orange Book. Not acquired within the last five years.
Rx0000078	Bristol Myers Squibb	03/31/2019	00003089321	ELIQUIS (Apixaban) 2.5 MG Tablet, Bottle of 60 Tablets	01/01/2019	25.14	444.17	02/24/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product was developed by BMS
Rx0000078	Bristol Myers Squibb	03/31/2019	00003089331	ELIQUIS (Apixaban) 2.5 MG Tablet, Bottle x 100 Tablets	01/01/2019	41.91	740.34	02/24/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product was developed by BMS
Rx0000078	Bristol Myers Squibb	03/31/2019	00003089470	ELIQUIS (Apixaban) 5 MG Tablet Bottle of 74 Tablets	01/01/2019	31.01	547.82	02/24/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product was developed by BMS
Rx0000078	Bristol Myers Squibb	03/31/2019	00003376474	ELIQUIS (Apixaban) 5 MG Tablet, 74 Tablets (1 blister pack of 42 tablets and 1 blister pack of 32 tablets)	01/01/2019	31.01	547.82	02/24/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product was developed by BMS
Rx0000078	Bristol Myers Squibb	03/31/2019	00003089421	ELIQUIS (Apixaban) 5 MG Tablet, Bottle of 60 Tablets	01/01/2019	25.14	444.17	02/24/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product was developed by BMS
Rx0000078	Bristol Myers Squibb	03/31/2019	00003089431	ELIQUIS (Apixaban) 5 MG Tablet, Hospital Unit-Dose Blister Package of 100	01/01/2019	41.91	740.34	02/24/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product was developed by BMS
Rx0000078	Bristol Myers Squibb	03/31/2019	00003218851	ORENCIA (Abatacept) 125 MG/ML Solution, 1ML Single Dose Prefilled Auto-injector, Package of 4 Auto-Injectors	01/01/2019	247.86	4378.89	02/18/2018	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product was developed by BMS
Rx0000078	Bristol Myers Squibb	03/31/2019	00003218811	ORENCIA (Abatacept) 125 MG/ML Solution, 1ml Single Dose Prefilled Syringe Package of 4 Syringes	01/01/2019	247.86	4378.89	02/18/2018	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product was developed by BMS
Rx0000078	Bristol Myers Squibb	03/31/2019	00003218710	ORENCIA (Abatacept) 250 MG Solution Vial W/ Syringe, Package contains 1 Vial	01/01/2019	62.78	1109.03	02/18/2018	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product was developed by BMS
Rx0000078	Bristol Myers Squibb	03/31/2019	00003281411	ORENCIA (Abatacept) 50 MG/0.4ML Solution, 0.4ML Single Dose Prefilled Syringe, Package of 4 Syringes	01/01/2019	247.86	4378.89	02/18/2018	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product was developed by BMS
Rx0000078	Bristol Myers Squibb	03/31/2019	00003281811	ORENCIA (Abatacept) 87.5 MG/0.7ML Solution, 0.7ML Single Dose Prefilled Syringe, Package of 4 Syringes	01/01/2019	247.86	4378.89	02/18/2018	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product was developed by BMS
Rx0000078	Bristol Myers Squibb	03/31/2019	00003085222	SPRYCEL (Dasatinib) 100 MG Tablet, Bottle of 30 Tablets	01/01/2019	774.72	13686.79	09/28/2026	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product was developed by BMS
Rx0000078	Bristol Myers Squibb	03/31/2019	00003085722	SPRYCEL (Dasatinib) 140 MG Tablet, Bottle of 30 Tablets	01/01/2019	774.72	13686.79	09/28/2026	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product was developed by BMS
Rx0000078	Bristol Myers Squibb	03/31/2019	00003052711	SPRYCEL (Dasatinib) 20 MG Tablet, Bottle of 60 Tablets	01/01/2019	429.85	7593.95	09/28/2026	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product was developed by BMS
Rx0000078	Bristol Myers Squibb	03/31/2019	00003052811	SPRYCEL (Dasatinib) 50 MG Tablet, Bottle of 60 Tablets	01/01/2019	859.69	15187.87	09/28/2026	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product was developed by BMS
Rx0000078	Bristol Myers Squibb	03/31/2019	00003052411	SPRYCEL (Dasatinib) 70 MG Tablet, Bottle of 60 Tablets	01/01/2019	859.69	15187.87	09/28/2026	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product was developed by BMS
Rx0000078	Bristol Myers Squibb	03/31/2019	00003085522	SPRYCEL (Dasatinib) 80 MG Tablet, Bottle of 30 Tablets	01/01/2019	774.72	13686.79	09/28/2026	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product was developed by BMS